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Glioblastoma (GBM) is a malignant brain tumor1 with a 
median survival of approximately 15  months and poor 
responses to current therapeutic approaches.2,3 Single-
cell RNA sequencing showed that individual tumors are 
composed of multiple molecular subtypes (classical, mes-
enchymal, proneural, and neural subtypes),  suggesting 
intratumor heterogeneity.4 Thus, a better understanding of 
the underlying molecular mechanisms that define tumor 
cell populations is crucial and may improve GBM therapy.
Large-scale molecular studies have identified key 
genetic alterations that may contribute to the development 
of GBM. Alterations in receptor tyrosine kinase (RTK)-
mediated signaling pathways have been reported to occur 
in 88% of GBM.5 As a regulator of RTK signaling, Sprouty 
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Abstract
Background. Sprouty2 (SPRY2), a feedback regulator of receptor tyrosine kinase (RTK) signaling, has been shown 
to be associated with drug resistance and cell proliferation in glioblastoma (GBM), but the underlying mechanisms 
are still poorly defined.
Methods. SPRY2 expression and survival patterns of patients with gliomas were analyzed using publicly available 
databases. Effects of RNA interference targeting SPRY2 on cellular proliferation in established GBM or patient-
derived GBM stemlike cells were examined. Loss- or gain-of-function of SPRY2 to regulate the tumorigenic cap-
acity was assessed in both intracranial and subcutaneous xenografts.
Results. SPRY2 was found to be upregulated in GBM, which correlated with reduced survival in GBM patients. 
SPRY2 knockdown significantly impaired proliferation of GBM cells but not of normal astrocytes. Silencing of 
SPRY2 increased epidermal growth factor-induced extracellular signal-regulated kinase (ERK) and Akt activation 
causing premature onset of DNA replication, increased DNA damage, and impaired proliferation, suggesting that 
SPRY2 suppresses DNA replication stress. Abrogating SPRY2 function strongly inhibited intracranial tumor growth 
and led to significantly prolonged survival of U87 xenograft-bearing mice. In contrast, SPRY2 overexpression pro-
moted tumor propagation of low-tumorigenic U251 cells.
Conclusions. The present study highlights an antitumoral effect of SPRY2 inhibition that is based on excessive 
activation of ERK signaling and DNA damage response, resulting in reduced cell proliferation and increased cyto-
toxicity, proposing SPRY2 as a promising pharmacological target in GBM patients.
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(SPRY) protein was first identified in Drosophila,6,7 and 4 
SPRY (SPRY1–4) proteins have been described in mam-
mals.8 Among these 4 isoforms, SPRY2 reveals the high-
est sequence homology across species.8 In most cancers, 
SPRY2 has been shown to be dysregulated, but the effects 
of SPRY2 on malignancy strongly depend on cancer type.9 
Tumor suppressive roles of SPRY2 are well established in 
breast, liver, lung, and prostate cancers,10–13 while in colon 
cancer, in which SPRY2 is highly expressed in undifferenti-
ated high-grade tumors14 and enhances proliferation and 
metastasis,15 SPRY2 acts like an oncogene.
In GBM, the function of SPRY2 is not well understood. An 
earlier study showed that SPRY2 protein levels are signifi-
cantly decreased in about 80% of human gliomas (World 
Health Organization grades II–IV), implying a putative 
tumor suppressing function.16 Conversely, SPRY2 knock-
down (KD) has been demonstrated to potentiate responses 
to RTK inhibitors and decrease proliferation in GBM cells.17 
More recently, transcriptome analysis revealed that glio-
mas with high expression of SPRY isoforms (SPRY1, -2, 
and -4) and low expression of neurofibromin 1 (NF1) 
and phosphatase and tensin homolog (PTEN) are associ-
ated with poor prognosis compared with tumors with a 
reversed expression pattern.18 Here, we provide evidence 
that SPRY2 inhibition confers high extracellular signal-
regulated kinase (ERK) activity and sensitizes GBM cells to 
DNA damage response, leading to decreased cell prolifer-
ation and reduced tumorigenicity.
Materials and Methods
Cell Lines and Cell Culture
Patient-derived primary GBM stemlike cells were obtained 
from IRCCS-AOU San Martino-IST (Genova, Italy).19 Cells 
were grown in serum-free medium (Dulbecco’s modified 
Eagle’s medium [DMEM]-F12/Neurobasal [1:1] with 1% B27 
[Thermo Fisher Scientific], 2 mM L-glutamine [Gibco] and 
supplemented with 20  ng/mL each of epidermal growth 
factor [EGF; Sigma] and fibroblast growth factor 2 [FGF2; 
provided by Dr P. Claus, Hannover]). Cells were cultured as 
monolayer on Matrigel (Corning). The standard GBM cell 
lines U87, T98G, U251, U118, U1242, and SF126 (provided 
by Dr M. Reindl, Innsbruck) were cultured in DMEM (Sigma) 
with 10% fetal bovine serum (FBS; Gibco), 1% antibiotic-
antimycotic (ABAM; Gibco), and 2 mM L-glutamine (Gibco). 
Human astrocytes (ScienCell) were maintained in the rec-
ommended medium (ScienCell) supplemented with 2% 
FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin. 
All cells were grown in 5% CO2 humidified incubator at 
37 °C. U87, T98G, and U251 cell lines were authenticated by 
short tandem repeat analysis (Microsynth) within the past 
12 months.
Plasmids and Reagents
For short hairpin (sh)RNA-mediated depletion, annealed 
oligonucleotide targeting SPRY2 (shRNA target: 
GCAGGTACATGTCTTGTCT) was inserted into pGLTR-puro 
plasmid for a stable and conditional RNA interference 
(RNAi) system.20 As a control, shRNA targeting luciferase 
was used. For stable transgene expression, lentiviral plas-
mids encoding VNP (Venus-NLS-PEST) or N-terminal, 
Flag-tagged SPRY2 were cloned. SPRY2S121A mutant, 
RNAi-resistant-SPRY2, or -luciferase were generated using 
site-directed mutagenesis. The mitogen-activated protein 
kinase kinase (MEK) inhibitor PD98059 (Sigma) was used 
to inhibit ERK activity.
Establishment of Stable Cell Lines
Lentiviral particles were produced by co-transfection of 
human embryonic kidney 293T cells with the lentiviral 
plasmids as well as helper plasmids psPAX2 and VSV-G. 
Culture media were harvested after 48 hours of transfec-
tion and further used for infection with 4 µg/mL polybrene 
(Sigma). Target cells were infected with 0.2  µm filtered 
lentivirus for 24 hours and cells expressing the respective 
transgene were selected using 2 µg/mL puromycin (Sigma). 
For stable expression of RNAi-insensitive-SPRY2 or -firefly 
luciferase, retroviral transduction was performed by trans-
fection of Phoenix cells with pQCXIN plasmid encoding the 
transgene, and transduced cells were selected with 500 µg/
mL G418 (Sigma). After transduction, transgene expres-
sion was analyzed by reverse transcription quantitative 
(RT-q) PCR. Detailed experimental procedures for RT-qPCR 
and immunostaining are described in the Supplementary 
Methods.
Immunoblotting
Total cell lysates were prepared followed by boiling and 
sonication. Equal amounts of proteins were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
transferred to nitrocellulose membrane (GE Healthcare). 
Membranes were blocked with 10% low fat skim milk 
(Marvel) and 0.5% nonyl phenoxypolyethoxylethanol 
(NP40) in phosphate buffered saline (PBS), and incubated 
Importance of the study
As a regulator of RTK signaling, SPRY2 is essential for 
GBM cell proliferation and tumorigenicity. As a con-
sequence of hyperactivation of ERK signaling, the 
inhibitory effect on cell proliferation by silencing of 
SPRY2 is specific to GBM but not to normal astrocytes, 
suggesting that GBM cells are strongly addicted to 
elevated SPRY2 expression. Low SPRY2 expression is 
associated with better prognosis in malignant glioma 
patients, suggesting that modulation of SPRY2 may 
provide a novel avenue for GBM therapies.
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with primary antibodies: anti-SPRY2 (Abcam, 1:1000), 
anti-α-tubulin (TAT1, 1:10000), anti-pERK (Cell Signaling 
Technology, 1:1000), anti-ERK (Cell Signaling Technology, 
1:1000), anti-pAkt (Cell Signaling Technology, 1:1000), anti-
Akt (Cell Signaling Technology, 1:1000), anti-poly(ADP-
ribose) polymerase (PARP) (Cell Signaling Technology, 
1:1000), and anti-γH2AX (Cell Signaling Technology, 1:1000). 
Bound antibodies were detected using goat anti-mouse or 
anti-rabbit horseradish peroxidase-linked secondary anti-
bodies (Dako) and enhanced chemiluminescence reagent 
(Thermo Fisher Scientific).
Cell Growth Measurement and Cell Cycle 
Analysis
For measuring cellular proliferation, cells were seeded at 
100 000 cells per well in 6-well plates and counted using a 
hemocytometer 4  days later. The values of doubling times 
were obtained applying the exponential growth formula and 
further used for calculation of doublings per day as previ-
ously reported.21 To measure cytotoxicity, trypan blue (Sigma)-
positive cells were counted. For cell cycle analysis, cells were 
harvested and fixed with 70% ethanol overnight at 4°C. The 
following day the cells were washed twice with PBS and incu-
bated with 40 µg/mL propidium iodide solution (Sigma) con-
taining 100 µg/mL RNase A (Promega) for 30 minutes at 37°C. 
The cell cycle phase was determined by flow cytometry (LSR-
Fortessa, BD Biosystems) and analyzed using FlowJo software.
GBM Xenograft Models
Six- to 8-week-old female Naval Medical Research Institute 
nu/nu mice were purchased from Janvier Labs. Mice 
were anesthetized with ketamine/xylazine and stereo-
tactically implanted with U87 (5  ×  105) or U251 (1  ×  106) 
cells in 5 μL PBS into the right striatum. Bioluminescence 
imaging was performed using the Lumina In Vivo Imaging 
System (PerkinElmer), as reported.22 Mice were sacrificed 
when animals showed more than 20% weight loss or 
neurological symptoms. Subcutaneous cell injection was 
performed with U87 (2 × 106) or U251 (1.5 × 106) cells in 
100 μL PBS. The width and length of subcutaneous tumor 
xenografts were measured every 4 to 5 days using a cali-
per. The tumor volume in cubic millimeters was calcu-
lated as width2 × length × 0.4. Mice were euthanized when 
the tumor volume exceeded 800 mm3. At the end of the 
study, subcutaneous tumors were excised for immuno-
histochemical analysis of Ki67. For inducible silencing of 
SPRY2, 0.5 mg/mL of doxycycline (Sigma) for subcutane-
ous implantation or 1 mg/mL of doxycycline for intracra-
nial implantation with 5% sucrose (Sigma) was freshly 
administered every 4–7 days into drinking water. All animal 
experiments were performed with the approval of the insti-
tutional review board and the Austrian Federal Ministry of 
Science (BMWFW-66.011/0041-WF/V/3b/2016).
Analysis of SPRY2 mRNA Expression and Patient 
Survival
The expression of SPRY isoforms in The Cancer Genome 
Atlas (TCGA) GBM5 GSE769623 and GSE3624524 datasets 
was examined using the R2 genomics analysis and visu-
alization platform (http://r2.amc.nl). For comparison with 
nontumor, lower-grade glioma or other cancer tissues, 
SPRY2 expression in TCGA and GSE429025 datasets was 
analyzed using ONCOMINE26 or The Cancer Immunome 
Atlas (https://tcia.at/home). The GlioVis data portal for visu-
alization and analysis of brain tumor expression datasets27 
was used for the patient survival analysis within TCGA5,28 
datasets.
Statistical Analysis
All experiments are represented as mean ± SEM or SD and 
analyzed using GraphPad Prism software version 7.0. For 
significance calculation, unpaired t-test or one-way ANOVA 
was used to compare differences between 2 independent 
groups or among multiple independent groups, respect-
ively. The statistical significance is indicated as *P < 0.05, 
**P < 0.01, and ***P < 0.001.
Results
Upregulation of SPRY2 Correlates with Reduced 
Overall Survival in GBM Patients
Sprouty genes (SPRY1–4), together with PTEN and NF1, 
are used as molecular signatures for clustering adult dif-
fuse gliomas.18 To investigate which SPRY isoforms correlate 
with the malignancy of GBM, we first compared the mRNA 
expression of 4 different SPRY isoforms in GBM using the 
R2 genomics analysis and visualization platform. Analysis 
of all 3 GBM microarray gene expression profiles5,23,24 dem-
onstrated that among the SPRY genes, SPRY2 was strongly 
expressed in GBM (Fig. 1A). In large transcriptome datasets, 
we next compared SPRY2 mRNA expression levels in 19 
different cancers and corresponding normal tissues. GBM 
expressed the highest levels of SPRY2 among different can-
cers (Supplementary Fig. S1A). Moreover, its expression in 
GBM was found to be significantly higher than that in nor-
mal brain tissues (Fig.  1B and Supplementary Fig.  S1A). 
SPRY2 expression correlated positively with glioma grade in 
the dataset of TCGA28 (Supplementary Fig. S1B). We further 
tested the above findings in culture, using normal human 
astrocytes, an established GBM cell line (U87), as well as 
patient-derived GBM stem cells  (GSCs) maintained in the 
absence of serum. SPRY2 expression in human astrocytes 
and GSC1 was relatively modest, whereas U87 and GSC2 
expressed high levels of SPRY2 (Fig.  1C). SPRY2 mRNA 
expression correlated well with protein levels in GBM-
derived cell lines (R2 = 0.615; Supplementary Fig. S1C, D).
Because the above data suggested a strong correlation 
between SPRY2 expression levels and malignancy, we next 
examined whether there was any correlation between SPRY2 
expression and survival of glioma patients. As reported pre-
viously,17 the Kaplan‒Meier plot indicates that GBM5 patients 
with low mRNA expression of SPRY2 had a significantly 
better clinical outcome (P < 0.001; Fig. 1D). Intriguingly, low 
expression of SPRY2 is associated with prolonged over-
all survival in glioma patients,28 regardless of isocitrate 
dehydrogenase mutation status (Supplementary Fig. S2).
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Inhibition of Cell Proliferation by Downregulation 
of SPRY2 Is GBM-specific
To understand the role of SPRY2 in GBM biology, we trans-
duced U87 cells with lentiviral vectors for doxycycline 
(Doxy)-inducible shRNA expression for SPRY2 KD (Fig. 2A) 
or luciferase as a control (Supplementary Fig.  S3A). 
Because long-term serum-cultured GBM cell lines can dif-
fer in several aspects from primary GBM cells,29 we also 
utilized primary cells (GSC1 and GSC2) from GBM patients 
to increase the clinical relevance of this analysis (Fig. 2B). 
Cell proliferation was significantly reduced in SPRY2 KD 
cell cultures but not in cells expressing shRNA target-
ing luciferase (Fig.  2C, D). Upon reconstitution of SPRY2 
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Fig. 1 SPRY2 is strongly expressed in GBM and its expression correlates with reduced overall survival in GBM patients. (A) The mRNA expres-
sion of 4 different SPRYs (SPRY1-4) in 3 GBM datasets using the R2 genomics analysis and visualization platform (http://r2.amc.nl). (B) SPRY2 
expression levels in GBM compared with that of nontumor samples. TCGA and GSE4290 datasets, including P-values, were analyzed using 
ONCOMINE. (C) Levels of endogenous SPRY2 protein in normal human astrocyte (HA), U87 and GBM stemlike cells (GSC1 and GSC2) as deter-
mined by immunoblot. (D) Overall survival differences among GBM patients are shown as Kaplan‒Meier survival curve with high and low mRNA 
expression of SPRY2 from TCGA dataset. ***P < 0.001 by the log-rank test.
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expression by retrovirus-mediated transduction of an 
RNAi-resistant version of SPRY2 in U87 tet-SPRY2sh cells, 
this proliferation defect could be restored, proving the spe-
cificity of the SPRY2-RNAi effect (Fig. 2A, C). Along with the 
inhibition of cell proliferation, a cytotoxic effect was also 
observed in U87 and GSC1 SPRY2 KD cells (Supplementary 
Fig. S3B, C). Thus, increased cell death as well as reduced 
generation time may both contribute to impaired prolifer-
ation. To determine whether knockdown of SPRY2 would 
also affect the proliferation of primary nontransformed 
cells, we also transduced normal human astrocytes for 
loss-of-function experiments (Fig. 2E). Intriguingly, silenc-
ing of SPRY2 had no effect on the proliferative capacity of 
human astrocytes (Fig. 2F), suggesting that SPRY2 might 
exert a GBM-specific activity.
Impaired Proliferation in SPRY2 KD Cells Depends 
on ERK Signaling
SPRY2 protein negatively regulates RTK-dependent signal-
ing in response to growth factors.30,31 To test the canonical 
function of SPRY2 in U87 and GSC1 cells, we examined sign-
aling downstream of EGF receptor activation in induced and 
non-induced SPRY2 KD cells. In response to EGF treatment, 
downregulation of SPRY2 resulted in a strong increase and 
prolonged duration of ERK activation in both U87 and GSC1 
cells (Fig.  3A). Similarly, Akt was also more strongly acti-
vated in SPRY2 KD cells than in controls. Interestingly, dur-
ing EGF stimulation, SPRY2 levels in GSC1 cells increased 
to levels similar to the basal expression levels of U87 cells 
(Fig. 3A). This suggests that in GSC1 cells, SPRY2 expression 
is still embedded in the negative feedback regulation loop 
downstream of RTK activation, while in U87 cells SPRY2 is 
constitutively expressed, which may be a result of the con-
tinued growth in high serum conditions, consistent with its 
function as a negative regulator of RTK signaling.
To investigate whether the consequence of SPRY2 KD 
on cell proliferation is dependent on hyperactivation 
of the ERK signaling pathway, we used the MEK inhibi-
tor PD98059 (MEKi), which attenuated ERK activity in 
a dose-dependent manner (Fig.  3B). Importantly, treat-
ment of PD98059 reversed the inhibitory effect on cell 
proliferation of SPRY2 KD (Fig. 3C), indicating that high 
ERK activity is required for SPRY2 KD-induced impaired 
proliferation.
Silencing of SPRY2 Causes Premature S-phase 
Entry and DNA Damage
The above experiment confirmed that SPRY2 is func-
tionally intact in both U87 and GSC1 cells, and exerts 
its canonical function as an inhibitor of mitogenic ERK 
activation. Despite this effect, however, silencing of 
SPRY2 reduced proliferation of GBM cells (Fig.  2). As 
oncogene-induced DNA replication stress results in 
DNA damage-induced cell cycle arrest, senescence, 
or apoptosis,32 we hypothesized that increased ERK 
activation due to knockdown of SPRY2 in growth 
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Fig. 2 SPRY2 suppression inhibits cell proliferation of GBM but not of normal human astrocytes. (A and B) U87, GSC1, or GSC2 cells express-
ing doxycycline-inducible SPRY2-shRNA were treated with or without 1 µg/mL doxycycline for 72 hours, and SPRY2 protein levels were deter-
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promoting conditions may also result in prema-
ture entry into S-phase and DNA replication stress. 
To examine whether SPRY2 KD accelerated cell cycle 
progression into S-phase, we performed bromod-
eoxyuridine (BrdU) incorporation assays in induced 
and non-induced SPRY2 KD cells. As can be seen in 
Fig. 4A, the number of BrdU-positive cells was signifi-
cantly increased in SPRY2 KD cells 4 hours after EGF 
stimulation. Furthermore, we performed immunoblot-
ting and immunostaining with a marker for DNA dam-
age to test whether SPRY2 KD induces DNA replication 
stress. As expected, phosphorylated H2AX (γH2AX), a 
marker for double-strand DNA breaks, was markedly 
increased in U87 and GSC1 SPRY2 KD cells (Figs.  3A 
and 4B, C). In addition, SPRY2 KD induced PARP cleav-
age, indicating the induction of apoptotic cell death 
(Fig.  4C). Thus, the reduced proliferation upon deple-
tion of SPRY2 might be due to DNA replication stress 
triggered by oncogenic activity (eg, the activation of 
the Ras-Raf-mitogen-activated protein kinase [MAPK] 
cascade in GBM).
Conditional Knockdown of SPRY2 Inhibits GBM 
Tumor Growth
To assess whether RNAi targeting SPRY2 exerts anti-
tumoral effects in vivo, we next performed intracranial 
implantation of U87 cells stably expressing a luciferase 
variant resistant to RNAi in female athymic mice (n =  5/
group). Three days before tumor implantation, oral doxy-
cycline treatment was initiated. Intracranial xenografts 
were then generated in Doxy-treated mice by implant-
ation of Doxy-inducible SPRY2-shRNA cells. As a 
control, Ctrl-shRNA cells were also used to exclude non-
specific effects of doxycycline treatment on tumor growth. 
Bioluminescence imaging showed the inhibited tumor 
growth in Doxy-treated tet-SPRY2sh tumor-bearing mice 
compared with control mice (Fig.  5A). Strikingly, bio-
luminescence signal was not present in Doxy-treated tet-
SPRY2sh mice (4/5) over 9 weeks, which translated into a 
prolonged survival of mice (P = 0.002; Fig. 5B). In contrast, 
Doxy-treated tet-Ctrlsh tumors grew substantially, reach-
ing the clinical endpoint (median survival 27 days) (Fig. 5A, 
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bodies. (B) Immunoblots for the indicated proteins in U87 tet-SPRY2sh cells (± Doxy) pretreated with the indicated concentrations of PD98059 or 
dimethyl sulfoxide (DMSO), and stimulated with EGF (20 ng/mL) for 20 minutes. (C) Measurement of cell proliferation of U87 tet-SPRY2sh cells (± 
Doxy) in the presence of DMSO or 10 µM PD98059. Mean ± SEM of at least 3 independent experiments. **P < 0.01, ***P < 0.001.
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B). Animal weight inversely correlated with tumor growth 
(Supplementary Fig. S4A). At 63 days post injection, dox-
ycycline treatment was terminated to further examine 
whether a subset of tumors resides in Doxy-treated tet-
SPRY2sh mice (n =  4). Two weeks after the termination, 
the tumor growth onset was observed in bioluminescence 
measurements (Supplementary Fig. S4B).
This pattern was also confirmed in subcutaneous 
xenografts. Subcutaneous tumor volumes steadily 
increased in Doxy-treated tet-Ctrlsh (n =  6) and Doxy-
untreated tet-SPRY2sh mice (n = 7) and reached volumes 
of 130.1 ± 11.95 mm3 and 136.0 ± 37.39 mm3, respectively, 
at 27  days post injection (Fig.  5C, inset). Conversely, 
tumors derived from Doxy-treated tet-SPRY2sh mice (n 
= 7) were much smaller (32.14 ± 3.65 mm3) (Fig. 5C, D). 
Doxycycline was newly administered or withdrawn in 
4 out of 7 mice in tet-SPRY2sh groups at day 27, when 
tumor size in the Doxy-treated and -untreated groups 
showed significant differences (Fig.  5C, arrow). After 
treatment, tumors derived from the previously Doxy-
untreated tet-SPRY2sh group revealed a substantial 
reduction in tumor size by 55% relative to control tumors 
over the course of the following 2 weeks (Fig.  5C). In 
contrast, the tumors derived from continuously Doxy-
treated tet-SPRY2sh group remained viable, but without 
evidence of tumor growth onset for 55 days. Two weeks 
after removal of doxycycline, tumors grew rapidly and 
were larger than continuously Doxy-treated tet-SPRY2sh 
tumors (Fig.  5C). In Doxy-withdrawn tet-SPRY2sh 
tumors, the number of Ki67-positive cells was signifi-
cantly increased compared with continuously Doxy-
treated tet-SPRY2sh tumors (Fig. 5E).
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Fig. 4 Silencing of SPRY2 induces premature S-phase entry and DNA damage response. (A) Starved U87 or GSC1 tet-SPRY2sh cells (± Doxy) 
were stimulated with EGF for 4 hours. BrdU was added into the medium 2 hours before fixation. Representative pictures (left panel) of BrdU-
positive cells in U87 tet-SPRY2sh cells (± Doxy). Scale bar = 50 µm. Quantification of BrdU-positive cells of U87 or GSC1 tet-SPRY2sh cells (± 
Doxy). Mean ± SEM of 3 independent experiments (right panel). *P < 0.05, **P < 0.01. Phosphorylated H2AX (B and C) and PARP cleavage (C) of 
U87 or GSC1 SPRY2 KD cells as determined by immunoblot or immunostaining. Scale bar = 20 µm.
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SPRY2 Overexpression Promotes Tumor 
Propagation of Low-Tumorigenic U251 Cells
To further examine the effect of SPRY2 on GBM tumor 
growth, we utilized U251 cells, which express very low 
levels of endogenous SPRY2, making them a suitable 
cell line for overexpression (OE) experiments (Fig.  6A). 
As phosphorylation of serine 121 was shown to be import-
ant for the functionality of SPRY2,33 we also generated U251 
cells expressing a SPRY2S121A mutant using lentiviral gene 
expression vectors (Fig. 6A). As a control for lentiviral gene 
expression, we transduced U251 cells with a lentiviral con-
struct expressing VNP (Venus-NLS-PEST) fluorescent pro-
tein. Proliferation capacity and cell cycle progression was 
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Fig. 5. Downregulation of SPRY2 inhibits U87 intracranial and subcutaneous tumor growth. (A) U87 tet-Ctrlsh or tet-SPRY2sh cells (0.5 million) 
expressing RNAi-resistant luciferase were intracranially injected in nude mice (n = 5/group) with administration of doxycycline. Representative 
image of bioluminescence at the indicated time point (left panel). Quantification of signal intensity presented as photons/sec/cm2/surface radi-
ance, *P < 0.05, mean ± SD (right panel). (B) Kaplan‒Meier survival curve; **P < 0.01 by the log-rank test. (C) U87 tet-Ctrlsh or tet-SPRY2sh cells 
(2 million) were subcutaneously injected in nude mice (n = 6–7/group) with or without administration of doxycycline. Early stage of subcutane-
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tet-SPRY2sh tumor-bearing mice is highlighted in orange. Tumor growth after doxycycline withdrawal in 4 out of 7 doxy-treated tet-SPRY2sh 
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comparable between U251 Ctrl and SPRY2 OE cells (Fig. 6B 
and Supplementary Fig. S5A, B), but SPRY2S121A mutant OE 
inhibited cell proliferation of U251 cells (Fig. 6B).
To test the effect of SPRY2 on U251 xenografts, U251 
cells expressing VNP (Ctrl, n =  8), SPRY2 (n =  9), or 
SPRY2S121A (n = 8) were subcutaneously injected into nude 
mice. As a result, U251 SPRY2 OE mice exhibited a 26% 
increase in tumor take rate compared with U251 Ctrl, while 
there was no tumor formation in the SPRY2 serine mutant 
(S121A) OE mice (Fig. 6C). U251 SPRY2 OE subcutaneous 
tumors were 7 times larger by volume compared with Ctrl 
at 102 days post injection (Fig. 6D). Similarly, the survival 
of orthotopic xenografted mice was reduced in the case of 
U251 SPRY2 OE transplants (median 70.5 days) compared 
with controls (median 91 days), while survival was signifi-
cantly increased in mice transplanted with SPRY2S121A OE 
cells (median 106 days) (P = 0.037; Fig. 6E).
Discussion
SPRY2 expression in GBM is higher than that in lower-
grade glioma and nontumor tissues. Among the estab-
lished GBM cell lines, U87 cells strongly express SPRY2, 
whereas U251 and T98G cells express low levels of SPRY2. 
U87 cells are a widely used cell line for tumor xenograft 
models, as they have a high tumorigenic potential in mice. 
In contrast, U251 and T98G cells are known to be less 
tumorigenic, implying that there might be a correlation 
between SPRY2 expression and tumorigenic capacity. 
Further supporting this hypothesis, the Kaplan–Meier plot 
indicates that GBM patients with low expression of SPRY2 
had significantly prolonged survival.
Cell proliferation is significantly impaired by shRNA-
mediated downregulation of SPRY2 in GBM cells. Our 
study showed that SPRY2 KD decreases cell proliferation 
with the concomitant increase of ERK and Akt activation. 
In contrast, inhibiting MEK activity restored proliferation 
of SPRY2 KD cells, indicating that the reduced proliferation 
upon SPRY2 KD is a consequence of excessive ERK signal-
ing, and antiproliferative efficacy of MEK inhibitor depends 
on the strength of ERK activation. This is consistent with 
previous findings that suppression of ERK levels or activity 
in both human and mouse primary cells prevented prolif-
eration arrest due to oncogenic stress induced by activated 
Ras.34 Zhang et al35 also reported that SPRY2 KD decreases 
cell proliferation of colon cancer cells in the presence of 
increased EGF-dependent ERK and Akt signaling and 
induction of the cyclin-dependent kinase inhibitor p21CIP1. 
We suggest here that decreased cell proliferation may 
be caused by oncogene-induced DNA replication stress 
because silencing SPRY2 causes premature S-phase entry 
and increased DNA damage. In parallel with these findings, 
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our data revealed that cytotoxicity and PARP cleavage are 
increased upon SPRY2 suppression. Thus, the canonical 
function of SPRY2 (ie, in dampening the MAPK pathway) 
appears to be required for proliferation and normal DNA 
replication by limiting oncogenic stress in primary GBM 
cells as well as established GBM cell lines.
It has been proposed that DNA replication stress can be 
exploited for cancer therapy because it is rarely detected 
in normal cells.32 Consistent with this, our study showed 
that the proliferation capacity of normal astrocytes is not 
attenuated by SPRY2 inhibition. Additionally, given that 
the expression of SPRY2 in normal tissues is significantly 
lower than in GBM tissues, nontumoral cells are unlikely 
targets for SPRY2 suppression.
Silencing of SPRY2 in cells grown in culture slowed 
down proliferation in part by inducing cell death. These 
effects were even more dramatic in vivo as knockdown 
of SPRY2 prevented tumor growth over the observation 
period of 9 weeks. Immunohistochemical analysis of Ki67 
showed that the strong inhibitory effect on tumor propa-
gation is likely due to proliferation arrest in response to 
SPRY2 suppression. After doxycycline termination at day 
63, tumor growth resumed with similar kinetics to control 
tumors. Similar results were obtained in heterotopic tumor 
transplantation experiments, demonstrating that SPRY2 
depletion by RNAi in vivo was not sufficient to eradicate 
tumor cells but more likely induced a reversible growth 
arrest, whose dormancy required continuous administra-
tion of doxycycline to downregulate SPRY2 expression.
Consistent with the hypothesis that SPRY2 is required for 
efficient tumor formation, SPRY2 OE enhanced tumor growth 
and reduced survival of tumor cells in xenotransplanted 
mice. As expected, ERK activity in U251 SPRY2 OE cells was 
decreased (data not shown), but this did not impact on prolif-
eration in vitro. The strong tumor-promoting effect of SPRY2 
OE in vivo most likely thus depends on additional factors such 
as tumor microenvironment or growth conditions in vivo 
compared with in vitro. The underlying mechanism for this 
effect needs to be addressed in future studies. Surprisingly, 
however, the SPRY2 serine mutant (S121A) OE strongly 
inhibited cell proliferation in culture and subcutaneous tumor 
growth. In line with this, the survival of mice was prolonged 
in mice intracranially implanted with U251 cells expressing 
mutants versus wild-type SPRY2 or control cells expressing 
VNP. That overexpression of SPRY2 (S121A) blocks prolifer-
ation and delays tumor formation in vivo was unexpected but 
may be due to a dominant negative effect, highlighting the 
potential of SPRY2 manipulation for tumor therapy.
We postulate that SPRY2 is important for cell prolifer-
ation and tumorigenicity in a subset of GBM. Targeting 
SPRY2 causes excessive ERK activation and sensitizes 
GBM cells to DNA damage response that eventually leads 
to decreased proliferation and reduced tumorigenic cap-
acity. The results of this study may provide a molecular 
basis for novel therapeutic strategies targeting GBM.
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